000			01641 a2200469 4500
005			20250516052519.0
264		0	_c20111207
008			201112s 0 0 eng d
022			_a1095-6859
024	7		_a10.1016/j.ygyno.2011.07.019 _2doi
040			_aNLM _beng _cNLM
100	1		_aHyman, David M
245	0	0	_aTopotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. _h[electronic resource]
260			_bGynecologic oncology _cNov 2011
300			_a196-9 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aDisease-Free Survival
650	0	4	_aDrug Resistance, Neoplasm
650	0	4	_aFallopian Tube Neoplasms _xdrug therapy
650	0	4	_aFemale
650	0	4	_aGenes, BRCA1
650	0	4	_aGenes, BRCA2
650	0	4	_aHumans
650	0	4	_aMiddle Aged
650	0	4	_aMutation
650	0	4	_aOvarian Neoplasms _xdrug therapy
650	0	4	_aPeritoneal Neoplasms _xdrug therapy
650	0	4	_aPlatinum _xtherapeutic use
650	0	4	_aRetrospective Studies
650	0	4	_aTopoisomerase I Inhibitors _xtherapeutic use
650	0	4	_aTopotecan _xtherapeutic use
700	1		_aZhou, Qin
700	1		_aArnold, Angela G
700	1		_aGrisham, Rachel N
700	1		_aIasonos, Alexia
700	1		_aKauff, Noah D
700	1		_aSpriggs, David
773	0		_tGynecologic oncology _gvol. 123 _gno. 2 _gp. 196-9
856	4	0	_uhttps://doi.org/10.1016/j.ygyno.2011.07.019 _zAvailable from publisher's website
999			_c21098445 _d21098445